A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)

医学 吉西他滨 内科学 奥沙利铂 叶黄素 伊立替康 临床终点 胃肠病学 养生 临床研究阶段 胰腺癌 无进展生存期 不利影响 外科 随机对照试验 癌症 化疗 结直肠癌
作者
Masato Ozaka,Kohei Nakachi,Satoshi Kobayashi,Akihiro Ohba,Hiroshi Imaoka,Takeshi Terashima,Hiroshi Ishii,Junki Mizusawa,Hiroshi Katayama,Tomoko Kataoka,Takuji Okusaka,Masafumi Ikeda,Naoki Sasahira,Haruo Miwa,Eishiro Mizukoshi,Naohiro Okano,Nobumasa Mizuno,Tomohisa Yamamoto,Yoshito Komatsu,Akiko Todaka
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:181: 135-144 被引量:50
标识
DOI:10.1016/j.ejca.2022.12.014
摘要

We compared the efficacy of modified 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) with that of gemcitabine plus nab-paclitaxel (GnP) for locally advanced pancreatic cancer (LAPC).Patients with untreated LAPC were randomly assigned (1:1) to receive mFOLFIRINOX or GnP. One-year overall survival (OS) was the primary endpoint. The major secondary end-points included progression-free survival (PFS), response rate (RR), carbohydrate antigen 19-9 (CA19-9) response, and adverse events. The sample size was 124 patients to select a more effective regimen with a minimum probability of 0.85 and to examine the null hypothesis of the 1-year OS <53%.Of the 126 patients enrolled from 29 institutions, 125 were deemed eligible. The 1-year OS was 77.4% (95% CI, 64.9-86.0) and 82.5% (95% CI, 70.7-89.9) in the mFOLFIRINOX and GnP arms, respectively. The median PFS was 11.2 (95% CI, 9.9-15.9) and 9.4 months (95% CI, 7.4-12.8) in the mFOLFIRINOX and GnP arms, respectively. The RR and CA19-9 response rate were 30.9% (95% CI, 19.1-44.8) and 57.1% (95% CI, 41.0-72.3) and 42.1% (95% CI 29.1-55.9) and 85.0% (95% CI, 70.2-94.3) in the mFOLFIRINOX and GnP arms, respectively. Grade 3-4 diarrhoea and anorexia were predominant in the mFOLFIRINOX arm.GnP was considered the candidate for a subsequent phase III trial because of its better RR, CA19-9 response, and mild gastrointestinal toxicities. Both regimens displayed higher efficacy in the 1-year survival than in the historical data of gemcitabine monotherapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
科研通AI5应助代何采纳,获得10
1秒前
3秒前
悦耳的子默完成签到,获得积分10
3秒前
CodeCraft应助998877剑指采纳,获得10
3秒前
悦耳的祥发布了新的文献求助10
4秒前
4秒前
子星发布了新的文献求助10
5秒前
浮游应助m30采纳,获得10
5秒前
Smiley发布了新的文献求助10
6秒前
Akim应助西子阳采纳,获得10
6秒前
Smiley发布了新的文献求助10
7秒前
贾舒涵发布了新的文献求助10
9秒前
王继刚完成签到,获得积分10
10秒前
11秒前
斯文败类应助斯文明杰采纳,获得10
11秒前
浮游应助科研通管家采纳,获得10
12秒前
充电宝应助科研通管家采纳,获得10
12秒前
852应助科研通管家采纳,获得10
12秒前
科研通AI5应助科研通管家采纳,获得10
12秒前
李健应助科研通管家采纳,获得10
12秒前
科研通AI2S应助科研通管家采纳,获得10
13秒前
彭于晏应助科研通管家采纳,获得30
13秒前
圆锥香蕉应助科研通管家采纳,获得20
13秒前
13秒前
13秒前
13秒前
科研通AI5应助科研通管家采纳,获得10
13秒前
Hello应助科研通管家采纳,获得10
13秒前
圆锥香蕉应助科研通管家采纳,获得20
13秒前
罗勍完成签到,获得积分10
13秒前
13秒前
英俊的铭应助科研通管家采纳,获得10
13秒前
充电宝应助科研通管家采纳,获得10
13秒前
馆长应助科研通管家采纳,获得30
13秒前
传奇3应助科研通管家采纳,获得10
13秒前
慕青应助科研通管家采纳,获得10
13秒前
科研通AI5应助科研通管家采纳,获得10
13秒前
李爱国应助科研通管家采纳,获得10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Inherited Metabolic Disease in Adults: A Clinical Guide 500
计划经济时代的工厂管理与工人状况(1949-1966)——以郑州市国营工厂为例 500
Sociologies et cosmopolitisme méthodologique 400
Why America Can't Retrench (And How it Might) 400
Another look at Archaeopteryx as the oldest bird 390
Partial Least Squares Structural Equation Modeling (PLS-SEM) using SmartPLS 3.0 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 物理化学 基因 催化作用 遗传学 冶金 电极 光电子学
热门帖子
关注 科研通微信公众号,转发送积分 4633293
求助须知:如何正确求助?哪些是违规求助? 4029304
关于积分的说明 12466863
捐赠科研通 3715514
什么是DOI,文献DOI怎么找? 2050190
邀请新用户注册赠送积分活动 1081753
科研通“疑难数据库(出版商)”最低求助积分说明 964055